I Tamimi1, B Nicolau2, H Eimar3, S Arekunnath Madathil2, A Kezouh4, I Karp5, F Tamimi6. 1. Hospital Regional Universitario de Malaga, Avenida Carlos Haya SN, 29010, Malaga, Spain. 2. Division of Oral Health and Society Research, Faculty of Dentistry, McGill University, 2001 McGill College Avenue, Montreal, QC, H3A 1G1, Canada. 3. Faculty of Medicine and Dentistry, University of Alberta, 2J2.00 WC Mackenzie Health Sciences Centre 8440 112 St. NW, Edmonton, Alberta, T6G 2R7, Canada. 4. Department of Epidemiology and Biostatistics, Centre for Clinical Epidemiology, Lady Davis Institute, 3755 Cote-Ste-Catherine Road, Montreal, QC, H3T 1E2, Canada. 5. Department of Epidemiology and Biostatistics, Kresge Building K214, Western University, London, Ontario, N6A 5C1, Canada. 6. Faculty of Dentistry, McGill University, 3640 University Street, Montreal, QC, H3A 2B2, Canada. faleh.tamimimarino@mcgill.ca.
Abstract
The objective of this study was to analyze the effect of acetylcholinesterase inhibitors (AChEIs) on the risk of osteoporotic fractures in Alzheimer patients. A nested case-control study was conducted on 1190 cases and 4760 controls. The use of AChEIs was found to decrease the risk of osteoporotic fractures in these patients. INTRODUCTION: The objective of this study is to estimate the extent to which the use of AChEIs is associated with a reduction in the risk of osteoporotic fractures. METHODS: A nested case-control study was conducted using data from the UK Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) database (1998-2013). The study cohort consisted of Alzheimer's Disease (AD) patients aged ≥ 65 years with no previous history of osteoporotic fractures at cohort baseline. Cases were individuals who suffered an osteoporotic fracture during the study period, whereas controls were subject who did not experience any osteoporotic fractures during the same period. Controls were drawn from the population time at risk while being matched to the cases in respect to age, sex, up-to-standard follow-up in the CPRD, calendar time, and duration of AD (control-to-case ratio: 4-to-1). Information on the use of AChEIs and the relevant potential confounders was ascertained from the CPRD database for all the cases and controls. RESULTS: We identified 1190 cases and 4760 controls. Compared to non-users, any use of AChEIs prior to the fracture was associated with a reduction in the fracture risk [adjusted odds ratio (OR) 0.80 (confidence interval (CI) 95%, 0.70-0.91)]. The use of AChEIs corresponding to a proportion of days covered of 0.8-1.0 was associated with a lower osteoporotic fracture risk compared to non-use [adjusted OR 0.76 (CI 95%, 0.66-0.87)]. CONCLUSIONS: In this study using large primary care databases, the use and treatment adherence to AChEIs were associated with a decreased risk of osteoporotic fractures in elderly AD patients.
The objective of this study was to analyze the effect of acetylcholinesterase inhibitors (AChEIs) on the risk of osteoporotic fractures in Alzheimerpatients. A nested case-control study was conducted on 1190 cases and 4760 controls. The use of AChEIs was found to decrease the risk of osteoporotic fractures in these patients. INTRODUCTION: The objective of this study is to estimate the extent to which the use of AChEIs is associated with a reduction in the risk of osteoporotic fractures. METHODS: A nested case-control study was conducted using data from the UK Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) database (1998-2013). The study cohort consisted of Alzheimer's Disease (AD) patients aged ≥ 65 years with no previous history of osteoporotic fractures at cohort baseline. Cases were individuals who suffered an osteoporotic fracture during the study period, whereas controls were subject who did not experience any osteoporotic fractures during the same period. Controls were drawn from the population time at risk while being matched to the cases in respect to age, sex, up-to-standard follow-up in the CPRD, calendar time, and duration of AD (control-to-case ratio: 4-to-1). Information on the use of AChEIs and the relevant potential confounders was ascertained from the CPRD database for all the cases and controls. RESULTS: We identified 1190 cases and 4760 controls. Compared to non-users, any use of AChEIs prior to the fracture was associated with a reduction in the fracture risk [adjusted odds ratio (OR) 0.80 (confidence interval (CI) 95%, 0.70-0.91)]. The use of AChEIs corresponding to a proportion of days covered of 0.8-1.0 was associated with a lower osteoporotic fracture risk compared to non-use [adjusted OR 0.76 (CI 95%, 0.66-0.87)]. CONCLUSIONS: In this study using large primary care databases, the use and treatment adherence to AChEIs were associated with a decreased risk of osteoporotic fractures in elderly ADpatients.
Authors: Abayomi N Ogunwale; Cathleen S Colon-Emeric; Richard Sloane; Robert A Adler; Kenneth W Lyles; Richard H Lee Journal: J Bone Miner Res Date: 2019-12-12 Impact factor: 6.741
Authors: Robert Josef Nachlinger; Vivien Kauschke; Katja Trinkaus; Thaqif El Khassawna; Christian Heiss; Katrin Susanne Lips Journal: J Musculoskelet Neuronal Interact Date: 2018-09-01 Impact factor: 2.041
Authors: Ahmad Tamimi; Faleh Tamimi; Malik Juweid; Abdelkarim A Al-Qudah; Amira Al Masri; Said Dahbour; Yakub Al Bahou; Abdelatif Shareef; Iskandar Tamimi Journal: J Musculoskelet Neuronal Interact Date: 2021-06-01 Impact factor: 2.041
Authors: Faez Saleh Al-Hamed; Ola M Maria; Jeff Phan; Ahmed Al Subaie; Qiman Gao; Alaa Mansour; Lina Abu Nada; Imane Boukhatem; Osama A Elkashty; Simon D Tran; Marie Lordkipanidzé; Zahi Badran; Faleh Tamimi Journal: Biomolecules Date: 2020-09-14